İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

novartis ireland limited - clomipramine hydrochloride - tablet - 75 milligram(s) - non-selective monoamine reuptake inhibitors; clomipramine

İsrail - İngilizce - Ministry of Health

bayer israel ltd - loratadine; pseudoephedrine sulfate - tablets prolonged release - loratadine 5 mg; pseudoephedrine sulfate 120 mg - loratadine - loratadine - relief of symptoms of seasonal allergic rhinitis when both the antihistaminic properties and the nasal decongestant activity are desired.

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

b & s healthcare - aminophylline hydrate - tablet prolonged release - 225 milligram

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - pseudoephedrine hydrochloride, quantity: 120 mg; fexofenadine hydrochloride, quantity: 60 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; pregelatinised maize starch; carnauba wax; colloidal anhydrous silica; stearic acid; macrogol 8000; hypromellose; macrogol 400 - for the relief of the symptoms of seasonal allergic rhinitis with nasal congestion when both the antiallergic properties of fexofenadine hydrochloride and the decongestant activity of pseudoephedrine hydrochloride are required.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pseudoephedrine hydrochloride, quantity: 30 mg; chlorphenamine maleate, quantity: 2 mg; paracetamol, quantity: 500.4 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; crospovidone; pregelatinised maize starch; povidone; purified water; erythrosine aluminium lake; stearic acid - temporary relief of the symptoms of sinus headache, pain and nasal congestion (including fever) and hay fever.

Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - ephedrine hydrochloride - oral tablet - 15mg

Birleşik Krallık - İngilizce - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - ephedrine hydrochloride - oral tablet - 30mg

İrlanda - İngilizce - HPRA (Health Products Regulatory Authority)

b & s healthcare - felodipine, ramipril - tablet prolonged release - 5/5 milligram - ace inhibitors and calcium channel blockers

Malta - İngilizce - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - pseudoephedrine hydrochloride, chlorphenamine maleate, paracetamol - tablet - paracetamol 325 mg pseudoephedrine hydrochloride 15 mg chlorphenamine maleate 1 mg - analgesics

ABD - İngilizce - NLM (National Library of Medicine)

endo usa, inc. - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none risk summary available data from randomized studies, case series, and reports of ephedrine sulfate use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.  however, there are clinical considerations (see clinical considerations) . in animal reproduction studies, decreased fetal survival and fetal body weights were observed in the presence of maternal toxicity after normotensive pregnant rats were administered 60 mg/kg intravenous ephedrine sulfate (12 times the maximum recommended human dose (mrhd) of 50 mg/day). no malformations or embryofetal adverse effects were observed when pregnant rats or rabbits were treated with intravenous bolus doses of ephedrine sulfate during organogenesis at doses 1.9 and 7.7 times the mrhd, respectively (see data) .  the estimated background risk of major birth defects and miscarriage for the indicated population are unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryofetal risk untreated hypotension associated with spinal anesthesia for cesarean section is associated with an increase in maternal nausea and vomiting. a decrease in uterine blood flow due to maternal hypotension may result in fetal bradycardia and acidosis. fetal/neonatal adverse reactions cases of potential metabolic acidosis in newborns at delivery with maternal ephedrine exposure have been reported in the literature. these reports describe umbilical artery ph of ≤7.2 at the time of delivery [see clinical pharmacology (12.3) ]. monitoring of the newborn for signs and symptoms of metabolic acidosis may be required. monitoring of infant’s acid‐base status is warranted to ensure that an episode of acidosis is acute and reversible. data animal data decreased fetal body weights were observed when pregnant rats were administered intravenous bolus doses of 60 mg/kg ephedrine sulfate (12 times the maximum recommended human dose (mrhd) of 50 mg based on body surface area) from gestation day 6-17. this dose was associated with evidence of maternal toxicity (decreased body weight of dams and abnormal head movements). no malformations or fetal deaths were noted at this dose. no effects on fetal body weight were noted at 10 mg/kg (1.9 times the mrhd of 50 mg). no evidence of malformations or embryo-fetal toxicity were noted in pregnant rabbits administered intravenous bolus doses up to 20 mg/kg ephedrine sulfate (7.7 times the maximum recommended human dose (mrhd) of 50 mg based on body surface area) from gestation day 6-20. this dose was associated with expected pharmacological maternal effects (increased respiration rate, dilated pupils, piloerection). decreased fetal survival and body weights in the presence of maternal toxicity (increased mortality) were noted when pregnant dams were administered intravenous bolus doses of 60 mg/kg epinephrine sulfate (approximately 12 times the mrhd based on body surface area) from gd 6 through lactation day 20. no adverse effects were noted at 10 mg/kg (1.9 times the mrhd). risk summary a single published case report indicates that ephedrine is present in human milk. however, no information is available on the effects of the drug on the breastfed infant or the effects of the drug on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ephedrine sulfate injection and any potential adverse effects on the breastfed child from ephedrine sulfate injection or from the underlying maternal condition. safety and effectiveness in pediatric patients have not been established. animal toxicity data in a study in which juvenile rats were administered intravenous bolus doses of 2, 10, or 60 mg/kg ephedrine sulfate daily from postnatal day 35 to 56, an increased incidence of mortality was noted at the high dose of 60 mg/kg.  the no-adverse-effect level was 10 mg/kg (approximately 1.9 times a maximum daily dose of 50 mg in a 60 kg person based on body surface area). clinical studies of ephedrine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. this drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. ephedrine and its metabolite are excreted in urine. in patients with renal impairment, excretion of ephedrine is likely to be affected with a corresponding increase in elimination half-life, which will lead to slow elimination of ephedrine and consequently prolonged pharmacological effect and potentially adverse reactions. monitor patients with renal impairment carefully after the initial bolus dose for adverse events. instructions for use ephedrine sulfate injection, ready to use pre-filled syringe for intravenous use. 5 ml syringe (5 mg/ml) single-patient-use pre-filled syringe important information:  - ephedrine is an alpha- and beta- adrenergic agonist and a norepinephrine releasing agent that is indicated in the treatment of clinically important hypotension occurring in the setting of anesthesia. storage of the ephedrine pre-filled syringes: - store ephedrine pre-filled syringes at room temperature between 59° to 86 °f (15° to 30 °c). - keep unused ephedrine pre-filled syringes in the original carton to protect from light and from physical damage. - do not refrigerate or freeze ephedrine. ephedrine dosing: - use package insert for all dosing information. - ephedrine pre-filled syringes are available as 5 mg/ml in 5 ml pre-filled syringes. supplies needed to give injection: - 1 ephedrine pre-filled syringe - gloves - alcohol wipes - 1 disposal container for disposal of used syringes pre-filled syringe figure a administration of ephedrine by intravenous injection: notes: ephedrine is administered undiluted by slow intravenous injection. the syringe should be administered with clean gloved hands. check the compatibility of the ephedrine with all other medications and any intravenous fluids the patient is currently receiving. step 1: - examine syringe for damage or cracks and ensure the luer cap is intact. do not use if the luer cap is missing, loose or damaged. - inspect and ensure the ephedrine liquid in the pre-filled syringe is clear and colorless. do not use if the liquid looks discolored, cloudy, or if the liquid contains any particulate matter. - check the expiration date on the syringe and confirm product has not expired. do not use if the expiration date has passed. step 2: check the intravenous site for signs of infiltration from fluid or medications leaking into surrounding tissue. step 3: thoroughly cleanse the injection port closest to the patient with alcohol prep pad. step 4: twist the tip cap to open see figure b figure b step 5: remove air from the syringe if necessary. figure c - with the tip of the syringe pointing up, tap the syringe barrel to make air bubbles rise to the top. - expel air and excess medication by pushing the plunger up until the edge of the plunger is at the graduation mark that corresponds to volume of the prescribed dose. see figure c step 6: connect the syringe to the injection port. step 7: if the intravenous line does not have backflow protection, pinch/clamp the intravenous tubing between intravenous bag and injection port. step 8: press down on the plunger of the pre-filled syringe to administer the medication by intravenous bolus. inject 5 mg to 10 mg by intravenous bolus at a time. - adjust dosage according to the blood pressure goal (i.e., titrate to effect). - do not exceed a total dosage of 50 mg. step 9: remove the syringe from injection port. step 10: if necessary, release the pinched intravenous tubing ensuring continuous flow of intravenous fluid. or manually flush the line after administration of ephedrine so there is no residual drug in the intravenous tubing. step 11: dispose of used syringe. safely throw away syringe(s) immediately after use into an appropriate medical waste container.